NCT06333769 2025-08-15
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
Fujian Cancer Hospital
Phase 2 Completed
Fujian Cancer Hospital
Medical Research Council
Medical Research Council
National Cancer Center, Korea